JP2005532262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532262A5 JP2005532262A5 JP2003565315A JP2003565315A JP2005532262A5 JP 2005532262 A5 JP2005532262 A5 JP 2005532262A5 JP 2003565315 A JP2003565315 A JP 2003565315A JP 2003565315 A JP2003565315 A JP 2003565315A JP 2005532262 A5 JP2005532262 A5 JP 2005532262A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- ion
- tri
- salt
- fluorobenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 39
- 238000000034 method Methods 0.000 claims 26
- 150000002500 ions Chemical class 0.000 claims 24
- 238000003384 imaging method Methods 0.000 claims 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 10
- 229910052757 nitrogen Chemical group 0.000 claims 10
- 229910052698 phosphorus Inorganic materials 0.000 claims 10
- 239000011574 phosphorus Substances 0.000 claims 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims 10
- 150000001768 cations Chemical class 0.000 claims 9
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 9
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- -1 hydroxy, amino Chemical group 0.000 claims 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 210000003470 mitochondria Anatomy 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 230000002438 mitochondrial effect Effects 0.000 claims 6
- 230000006907 apoptotic process Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 150000001450 anions Chemical class 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 210000001700 mitochondrial membrane Anatomy 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 238000002600 positron emission tomography Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000006481 2-iodobenzyl group Chemical group [H]C1=C([H])C(I)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 1
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- 125000006483 4-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1I)C([H])([H])* 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 230000009946 DNA mutation Effects 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000006277 halobenzyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004898 mitochondrial function Effects 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35456302P | 2002-02-06 | 2002-02-06 | |
| PCT/US2003/003740 WO2003065882A2 (en) | 2002-02-06 | 2003-02-06 | Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005532262A JP2005532262A (ja) | 2005-10-27 |
| JP2005532262A5 true JP2005532262A5 (enExample) | 2006-01-05 |
| JP4530665B2 JP4530665B2 (ja) | 2010-08-25 |
Family
ID=27734391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565315A Expired - Fee Related JP4530665B2 (ja) | 2002-02-06 | 2003-02-06 | 放射性標識された親油性の塩を使用することによる、ミトコンドリアのための非浸襲性の画像診断技術 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8524193B2 (enExample) |
| EP (1) | EP1474177A4 (enExample) |
| JP (1) | JP4530665B2 (enExample) |
| CN (2) | CN101838289A (enExample) |
| AU (1) | AU2003217349B2 (enExample) |
| CA (1) | CA2474142C (enExample) |
| NZ (1) | NZ534496A (enExample) |
| TW (1) | TWI266634B (enExample) |
| WO (1) | WO2003065882A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7344702B2 (en) * | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| US8524193B2 (en) * | 2002-02-06 | 2013-09-03 | The Johns Hopkins University | Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts |
| IL173807A (en) | 2003-08-22 | 2014-02-27 | Antipodean Pharmaceuticals Inc | Antioxidant amphiphilic compounds, histoquinone history and pharmaceutical preparations containing them |
| US7888334B2 (en) | 2003-08-22 | 2011-02-15 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
| AU2011203177B2 (en) * | 2004-02-24 | 2012-04-26 | The General Hospital Corporation | Catalytic radiofluorination |
| AU2005216949B2 (en) * | 2004-02-24 | 2011-09-22 | The General Hospital Corporation | Catalytic radiofluorination |
| US8257680B1 (en) * | 2004-02-24 | 2012-09-04 | The General Hospital Corporation | Catalytic radiofluorination |
| US7485283B2 (en) | 2004-04-28 | 2009-02-03 | Lantheus Medical Imaging | Contrast agents for myocardial perfusion imaging |
| US7738096B2 (en) | 2004-10-21 | 2010-06-15 | University Of Georgia Research Foundation, Inc. | Surface enhanced Raman spectroscopy (SERS) systems, substrates, fabrication thereof, and methods of use thereof |
| JP2006315958A (ja) * | 2005-05-10 | 2006-11-24 | Nihon Medi Physics Co Ltd | 放射性ハロゲン標識有機化合物の製造方法 |
| US7824659B2 (en) | 2005-08-10 | 2010-11-02 | Lantheus Medical Imaging, Inc. | Methods of making radiolabeled tracers and precursors thereof |
| WO2008015392A1 (en) * | 2006-08-03 | 2008-02-07 | Hammersmith Imanet Limited | Fluoride drying method |
| WO2008098304A1 (en) * | 2007-02-16 | 2008-08-21 | The University Of Sydney | Carborane-phosphonium compounds and their use in boron neutron capture therapy and imaging |
| EP1990310A1 (en) * | 2007-04-23 | 2008-11-12 | Trasis S.A. | Method for the preparation of reactive 18F fluoride, and for the labeling of radiotracers, using a modified non-ionic solid support and without any evaporation step |
| WO2008151003A2 (en) * | 2007-05-30 | 2008-12-11 | Children's Medical Center Corporation | Novel fluorine-18 labeled rhodamine derivatives for myocardial perfusion imaging with positron emission tomography |
| US9717896B2 (en) | 2007-12-18 | 2017-08-01 | Gearbox, Llc | Treatment indications informed by a priori implant information |
| US20090287120A1 (en) | 2007-12-18 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
| US8636670B2 (en) | 2008-05-13 | 2014-01-28 | The Invention Science Fund I, Llc | Circulatory monitoring systems and methods |
| US8388936B2 (en) * | 2008-02-22 | 2013-03-05 | Mcw Research Foundation, Inc. | In vivo mitochondrial labeling using positively-charged nitroxide enhanced and gadolinium chelate enhanced magnetic resonance imaging |
| US8388931B2 (en) * | 2008-02-29 | 2013-03-05 | Marcos Lopez | 99m Tc-labeled triphenylphosphonium derivative contrasting agents and molecular probes for early detection and imaging of breast tumors |
| DK2257315T3 (da) | 2008-02-29 | 2020-01-27 | Lantheus Medical Imaging Inc | Kontrastmidler til anvendelser omfattende perfusionsbilleddannelse |
| JP5501339B2 (ja) | 2008-03-21 | 2014-05-21 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物 |
| CA3013503A1 (en) | 2008-04-25 | 2009-10-29 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
| JP5322527B2 (ja) * | 2008-07-17 | 2013-10-23 | 浜松ホトニクス株式会社 | アポトーシスの検出に適した化合物 |
| JP5662416B2 (ja) | 2009-04-15 | 2015-01-28 | ランセウス メディカル イメージング， インコーポレイテッド | アスコルビン酸による放射性医薬組成物の安定化 |
| CA2767475A1 (en) | 2009-07-10 | 2011-01-13 | Bayer Pharma Aktiengesellschaft | Usage of low to medium-pressure liquid chromatography for the purification of radiotracers |
| TWI664169B (zh) | 2010-02-08 | 2019-07-01 | 藍瑟斯醫學影像公司 | 用於合成造影劑及其中間體之方法及裝置 |
| GB201005624D0 (en) * | 2010-04-01 | 2010-05-19 | Medical Res Council | Probe |
| US9205156B2 (en) | 2010-05-27 | 2015-12-08 | Hadasit Medical Research Services & Development Limited | Molecular imaging agents |
| KR101172157B1 (ko) | 2010-05-27 | 2012-08-07 | 전남대학교산학협력단 | 미토콘드리아 영상을 위한 방사성 약물의 제조 방법 |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| CN102898470B (zh) * | 2012-11-02 | 2014-12-10 | 北京师范大学 | 一类新型有机膦化合物及其制备方法和应用 |
| JP6527516B2 (ja) | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
| KR20170063949A (ko) | 2014-10-06 | 2017-06-08 | 엑시큐어, 인크. | 항-ｔｎｆ 화합물 |
| WO2016072104A1 (ja) * | 2014-11-05 | 2016-05-12 | 国立大学法人東北大学 | ホスホニウム化合物およびその製造方法 |
| TWI611795B (zh) * | 2016-07-18 | 2018-01-21 | 許百靈 | 多針孔單光子ｓｐｅｃｔ心肌血流絕對定量方法與用途 |
| CN107233585B (zh) * | 2017-06-09 | 2021-01-22 | 四川大学华西医院 | 黄连素或其衍生物在制备心肌灌注显像剂中的用途 |
| MX2020000387A (es) | 2017-07-13 | 2020-08-17 | Univ Northwestern | Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos. |
| PL239871B1 (pl) * | 2018-09-05 | 2022-01-24 | Synektik Spolka Akcyjna | Znakowany radioizotopem związek czwartorzędowej soli amoniowej wielopierścieniowej aminy aromatycznej, zastosowanie znakowanego radioizotopem związku w metodzie diagnostycznej pozytonowej tomografii emisyjnej, a także kompozycja farmaceutyczna zawierająca znakowany radioizotopem związek czwartorzędowej soli amoniowej wielopierścieniowej aminy aromatycznej |
| CN110577478A (zh) * | 2018-10-25 | 2019-12-17 | 南方医科大学南方医院 | 一种正电子探针及其制备方法与应用 |
| US20220347323A1 (en) * | 2019-09-18 | 2022-11-03 | The Regents Of The University Of California | Positron Emission Tomography Guided Delivery of Mitochondral Complex I Inhibitors |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4446123A (en) * | 1982-10-13 | 1984-05-01 | Hahnemann University | Process of radioimaging the myocardium of mammals utilizing radiolabeled lipophilic cations |
| US6187284B1 (en) | 1997-09-03 | 2001-02-13 | Immunomedics, Inc. | Fluorination of proteins and peptides for F-18 positron emission tomography |
| JPH11295494A (ja) * | 1998-04-08 | 1999-10-29 | Nippon Meji Physics Kk | ［ｆ−１８］−フッ化物イオンの製造方法 |
| AU2001271248A1 (en) * | 2000-04-28 | 2001-11-12 | Duke University | 18f-labeled choline analogs |
| DE60134366D1 (de) * | 2000-06-21 | 2008-07-24 | Canon Kk | Elektrophotographisches photoempfindliches Element, Prozesskartusche und elektrophotographischer Apparat |
| US8524193B2 (en) * | 2002-02-06 | 2013-09-03 | The Johns Hopkins University | Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts |
| CA2494231A1 (en) | 2002-08-01 | 2004-04-22 | The Johns Hopkins University | Techniques for identifying molecular structures and treating cell types lining a body lumen using fluorescence |
-
2003
- 2003-02-06 US US10/503,690 patent/US8524193B2/en not_active Expired - Fee Related
- 2003-02-06 CA CA2474142A patent/CA2474142C/en not_active Expired - Fee Related
- 2003-02-06 NZ NZ534496A patent/NZ534496A/en not_active IP Right Cessation
- 2003-02-06 AU AU2003217349A patent/AU2003217349B2/en not_active Ceased
- 2003-02-06 TW TW092102375A patent/TWI266634B/zh not_active IP Right Cessation
- 2003-02-06 CN CN200910221879A patent/CN101838289A/zh active Pending
- 2003-02-06 WO PCT/US2003/003740 patent/WO2003065882A2/en not_active Ceased
- 2003-02-06 JP JP2003565315A patent/JP4530665B2/ja not_active Expired - Fee Related
- 2003-02-06 EP EP03713392A patent/EP1474177A4/en not_active Withdrawn
- 2003-02-06 CN CN03803440A patent/CN100577213C/zh not_active Expired - Fee Related
- 2003-02-06 US US10/360,566 patent/US7112318B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532262A5 (enExample) | ||
| JP7277113B2 (ja) | Ｐｓｍａ結合剤及びその使用 | |
| Carlson et al. | Small animal absorbed radiation dose from serial micro-computed tomography imaging | |
| Carlucci et al. | Dual-modality optical/PET imaging of PARP1 in glioblastoma | |
| Chakraborty et al. | Comparative studies of 177Lu–EDTMP and 177Lu–DOTMP as potential agents for palliative radiotherapy of bone metastasis | |
| Boschi et al. | Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS (AHX)-HBED-CC PSMA ligand | |
| Laforest et al. | Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET | |
| Kalidindi et al. | A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals | |
| Lee et al. | Radiation dose estimation using preclinical imaging with‐metaiodobenzylguanidine (MIBG) PET | |
| Das et al. | 170Tm-EDTMP: a potential cost-effective alternative to 89SrCl2 for bone pain palliation | |
| Louw et al. | Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model | |
| JP2010529088A5 (enExample) | ||
| Seo et al. | Tumor dosimetry using [124I] m-iodobenzylguanidine microPET/CT for [131I] m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model | |
| Grudzinski et al. | A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety | |
| Lawrence et al. | PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives | |
| Yousefnia et al. | Estimated human absorbed dose of 177Lu–BPAMD based on mice data: Comparison with 177Lu–EDTMP | |
| Nakata et al. | Comparative evaluation of [18F] DiFA and its analogs as novel hypoxia positron emission tomography and [18F] FMISO as the standard | |
| Hodolic et al. | Hypoxia PET tracers in EBRT dose planning in head and neck cancer | |
| Zou et al. | 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results | |
| Vaez-Tehrani et al. | Estimation of human absorbed dose for 166Ho-PAM: comparison with 166Ho-DOTMP and 166Ho-TTHMP | |
| Yousefnia et al. | Estimated human absorbed dose of a new 153Sm bone seeking agent based on biodistribution data in mice: Comparison with 153Sm-EDTMP | |
| Hino-Shishikura et al. | Biodistribution and radiation dosimetry of [18F]-5-fluorouracil | |
| Høyvik et al. | Therapeutic evaluation of [212Pb] Pb-AB001 and [177Lu] Lu-PSMA-617 in a mouse model of disseminated prostate cancer | |
| Amin et al. | Radiolabeling of thioguanine with 125 I for diagnosis and therapy: in vitro and in vivo evaluation | |
| Vaez-Tehrani et al. | Human absorbed dose estimation for a new 175Yb-phosphonate based on rats data: Comparison with similar bone pain palliation agents |